The combination antiretroviral therapy (cART) inhibit HIV replication effectively. However,
synergy among these drugs has not been well considered. The dose of drugs used as monotherapy
is the same as that used in combination therapy. Tenofovir+lamivudine+efavirenz is still the
first line regimen of cART in developing countries. The side effects of these drugs are
related to the concentration of drugs. Based on our previous data, we aim to evaluate whether
reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side effects
while not scarifying their virological efficacy.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Public Health Clinical Center
Collaborators:
The Second Hospital of Nanjing Medical University Yunnan Provincial Infectious Disease Hospital